Bordetella pertussis Antibodies

Santa Cruz Biotechnology features a diverse variety of Bordetella pertussis monoclonal antibodies for research focused on understanding this important pathogen. Bordetella pertussis Antibodies are validated for various techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Bordetella pertussis is the causative agent of whooping cough, a highly contagious respiratory disease that poses significant health risks, particularly to infants and young children. The study of Bordetella pertussis is crucial for developing effective vaccines and therapeutic strategies, as well as for understanding its mechanisms of pathogenicity and immune evasion. Research utilizing Bordetella pertussis monoclonal antibodies enables investigation of bacterial proteins and their roles in infection and disease progression. Understanding the molecular mechanisms of Bordetella pertussis infection can lead to improved treatment approaches and prevention strategies. Exploring host-pathogen interactions through detailed protein analysis helps reveal potential therapeutic targets. Investigating virulence factors and their regulation provides essential information for vaccine development. Santa Cruz Biotechnology monoclonal antibodies for Bordetella pertussis research support scientists worldwide in advancing our understanding of infectious diseases and developing more effective treatments.